Advertisement
Dr. Umansky's presentation entitled "Transrenal Nucleic Acids: FromProof-of-Principle to Clinical Tests" will describe the most recentachievements in Tr-DNA/RNA technology and development of specific tests.
Advertisement
The CNAPS meetings, held every two years, are devoted to a new directionin molecular diagnostics, the use of nucleic acids from bodily fluids such asplasma and urine for development of clinical tests. These tests can be usedfor diagnosis and monitoring of pathologies, including prenatal diagnostics,oncology, organ transplantation, infectious diseases, and others. CNAPSmeetings include forums of professionals and leaders in the field of cell-freecirculating nucleic acids and their practical applications. Additionalinformation is available at www.cnaps5moscow.ru.
Dr. Umansky will present data on practical applications of new methods ofTr-NA isolation and use of "ultrashort" PCR amplicons for developing prenataltests, as well as tests in areas of oncology and infectious diseases. He willalso discuss how new techniques for Tr-NA purifications led to the discoveryof both ubiquitous and transrenal tissue-specific microRNA (miRNA) in theurine. Qualitative and quantitative analysis of urinary miRNA significantlyexpands diagnostic applications of the Xenomics proprietary Tr-NA technology.
Xenomics' proprietary Tr-NA technology utilizes urine samples, rather thaninvasive blood or other samples. Fragmented cellular DNA, RNA, and whole miRNAfrom throughout the body cross the kidney barrier and accumulate in the urineproviding vital information about a wide range of conditions inside the body.The Company believes this new technology will foster fundamental improvementsin safety, accuracy and functionality of testing in the field of moleculardiagnostics, currently a $1.5 billion segment of the healthcare industry.
About Xenomics, Inc.
Xenomics is a molecular diagnostics company that focuses on thedevelopment of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics'patented technology uses safe and simple urine collection and can be appliedto a broad range of applications, including prenatal testing, tumor detectionand monitoring, tissue transplantation, infectious disease detection, genetictesting for forensic identity determination, drug development, and research tocounter bioterrorism. Scientists from Xenomics were the first to report thatfragments of DNA from normal cell death cross the kidney barrier and can bedetected in urine. The Company believes that its technology will opensignificant new markets in the molecular diagnostics field. Xenomics has threeissued U.S. patents covering different applications of the technology formolecular diagnostics and genetic testing and a European patent for theCompany's prenatal testing applications, and numerous pending patentapplications. For more investor-specific information, including daily andhistorical Company stock quote data, recent news releases and an Investor FactSheet, please visit http://www.xenomics.com. Xenomics is also listed on theFrankfurt Stock Exchange under the symbol XE7.
Forward-Looking Statements
Certain statements made in this press release are forward-looking. Suchstatements are indicated by words such as "expect," "might," "should,""anticipate" and similar words indicating uncertainty in facts and figures.Although Xenomics believes that the expectations reflected in suchf
